anticancer/necrosis

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 88 rezilta yo

Method of detecting Kawasaki disease using anti-tumor necrosis antibody

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This invention relates to a method of detecting a substance reactive with an anti-tumor necrosis factor antibody in a body fluid of a subject so as to determine the diseased condition of the subject, monoclonal antibodies which can be used in this detection method, and a detection kit for

Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Rheumatic diseases are the most common chronic inflammatory disorders. In Germany alone, one million patients suffer from immunologically mediated rheumatic diseases including rheumatoid arthritis (RA), spondyloarthropathies (SpA) and systemic autoimmune diseases like systemic lupus

Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumour necrosis factor alpha (TNF.alpha. or TNF) treatment to assess the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or

Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumour necrosis factor alpha (TNF.alpha. or TNF) treatment to asses the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or

Anti-tumor necrosis factor-alpha agents and uses thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention relates to anti-Tumor Necrosis Factor polypeptides comprising one or more antibody single variable domains, or antigen-binding fragments thereof, in particular, dimers comprising two light chain variable domains that have high solubility. It also relates

Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the field of methods and compositions for the treatment of hypotension. The invention also relates to the field of combination therapeutic regimens particularly those which include a regimen of a particularly

Combination therapy using antitumor immunotoxins with tumor necrosis factor

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The invention relates to use of a combination of tumor necrosis factor (TNF) and a suitable immunotoxin in the treatment of cancer in mammals. In particular, it relates to therapeutic or prophylactic antitumor treatment in mammals using simultaneous or alternate administration

Method of treating bacterial meningitis with anti-tumor necrosis factor antibody

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD This application is concerned generally with a treatment of infection and specifically with the use of monoclonal antibodies that bind to TNF to treat bacterial meningitis. PRIOR ART Bacterial meningitis remains one of the more difficult management problems in clinical medicine. Evidence

Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention is directed to an HDM-2-targeting cancer treatment. Specifically, the present invention is directed to methods of various cancer treatments that target HDM-2 in cancer cells, killing cancer cells by necrosis while not affecting normal, non-cancerous

Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The invention relates to methods of effectively treating various forms of cancer and screening candidate cancer treatments and compounds. Specifically, the present invention is directed to the use of novel compounds and methods to treat cancer and non-cancerous cells and cause

Mutant tumor necrosis factor proteins

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION Tumor necrosis factor .alpha. (TNF.alpha.) is a cytokine primarily produced by activated macrophages. TNF.alpha. stimulates T-cell and B-cell proliferation and induces expression of adhesion molecules on endothelial cells. This cytokine also plays an important role in

Muteins of tumor necrosis factor

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This invention relates to a novel physiologically active polypeptide, a DNA fragment encoding the polypeptide, a recombinant plasmid containing the DNA fragment, a recombinant microorganism cell transformed with the plasmid, a method of producing a novel physiologically active polypeptide using the

Products containing a lithium salt and a tumor necrosis factor

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The present invention relates to products containing a lithium salt and a tumor necrosis factor, and to the use of lithium salts for enhancing the action of tumor necrosis factors. It has already been disclosed that tumor necrosis factor a (TNF-.alpha.) or tumor necrosis factor .beta. (TNF-.beta.,

Method of identifying compounds that induce cell death by necrosis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION Cell death plays an important role in development, tissue homeostasis, and degenerative diseases. Two major forms of cell death have been described: apoptosis and necrosis. Apoptosis, also called programmed cell death, is an energy-driven process by which a cell actively

Fusion protein comprising tumor necrosis factor related apoptosis inducing ligand and integrin ligand and use thereof

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION This present invention relates to the biotechnological field. BACKGROUND OF THE INVENTION Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily. Similar to other members of the tumor necrosis factor superfamily,

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye